The short answer
Large supplemental fenugreek doses can cause a harmful glucose drop, so use with glipizide warrants caution. The size of the exact interaction is unknown, and ordinary food use is a different exposure.
What this answer covers
Trigonella foenum-graecum seed and extract supplements; culinary amounts, whole seed and hydroalcoholic extracts are not equivalent.
- Supplement or preparation
- Trigonella foenum-graecum
- Medication ingredient
- glipizide
Why the precaution is reasonable
NCCIH warns that large fenugreek doses may cause a harmful drop in glucose. Glipizide itself can cause severe hypoglycemia. Together these support reviewing supplement use, without proving a fixed risk for this pair.
A small trial had mixed glucose findings
A seed-extract study found improvements in some glucose and insulin response measures, but fasting and two-hour glucose did not differ between groups. It involved newly diagnosed patients and did not test glipizide co-use.
Seed preparations differ
The trial used a hydroalcoholic seed extract. A food portion, powdered seed, concentrated capsule or blended product can give a different exposure. Neither the study nor the general warning defines a safe glipizide combination dose.
Use a glucose plan
Discuss the exact product and amount with the diabetes team before starting or changing it. Follow your established glucose-monitoring and low-glucose treatment plan; do not adjust glipizide yourself. There is no established hour-based spacing rule that prevents a possible glucose effect.
Evidence and practical considerations
Side effects & toxicity
Large-dose fenugreek hypoglycemia guidance plus glipizide risk supports a conditional precaution; direct pair incidence is unestablished.
- Exact scope
- Trigonella foenum-graecum seed and extract supplements; culinary amounts, whole seed and hydroalcoholic extracts are not equivalent. with Oral glipizide RxCUI4821 IN, immediate and extended release distinguished.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Exact source preparation, medication and endpoint limits apply; no universal dose change or spacing.
Factors that may matter: Formulation; Dose and duration; Meal pattern; Other glucose-lowering agents; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25patients with mild to moderate type 2 diabetes.
Some glucose/insulin AUC measures improved, but fasting and two-hour glucose did not differ between groups.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
25newly diagnosed patients; not a glipizide co-use trial or clinically low glucose endpoint. Abstract has an implausible glucose-AUC numeric transcription, so exact AUC values are not reproduced.
Source 4: federal health guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Large doses may cause a harmful fall in glucose; evidence for glycemic benefit is limited by study quality.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
No glipizide-specific risk rate or safe threshold.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glipizide article preserving formulation, preparation and glucose endpoint distinctions. | |
| Research summary published |
Article revision: 1e0929f848869ad7
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.